Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension

Phase 4TerminatedNCT00471068

Alcon Research46 enrolled

Overview

To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

TravatanDRUG

Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)

CosoptDRUG

treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)

Placebo (Timolol Vehicle)DRUG

Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with open-angle glaucoma or ocular hypertension Exclusion Criteria: * By Age

Locations (1)

Coimbra

Coimbra, Portugal

Outcomes

Primary Outcomes

Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment

IOP measured at week 6 minus IOP measured at baseline

Time frame: At week 0 and week 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.